159 results on '"Weller M."'
Search Results
2. HSD91 High Costs, Low Quality of Life, Reduced Survival, and Room for Improving Treatment: An Analysis of Burden and Unmet Needs in Glioma
3. OA18.05 Tumor Immune Microenvironment Profiling in Oligometastatic Non-Small Cell Lung Cancer with Brain Metastases
4. Leptomeningeal metastasis from solid tumours: EANO–ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
5. Immunotherapy: MACROPHAGE-DRUG CONJUGATE AS A CELL-BASED THERAPY FOR GLIOBLASTOMA
6. 588 Influence of pathogenic filaggrin variants on dupilumab treatment in atopic dermatitis
7. Amélioration des critères combinés issus d’un domaine patient et de domaines de la maladie dans la dermatite atopique (DA) modérée à sévère et traités par upadacitinib
8. Association of pre-radiotherapy tumor burden and overall survival in newly diagnosed glioblastoma adjusted for MGMT promoter methylation status
9. Efficacité de l’upadacitinib versus dupilumab dans la dermatite atopique modérée à sévère : analyse du temps de maintien de réponse dans l’étude Heads Up
10. Analyse incrémentale sur l’amélioration des lésions cutanées avec upadacitinib versus dupilumab dans la dermatite atopique (AD) modérée à sévère : résultats de l’étude Heads Up
11. EANO–ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up of patients with brain metastasis from solid tumours
12. 126 Serum dupilumab levels after 16 weeks of treatment are not associated with treatment response or side effects in atopic dermatitis patients
13. 025 Immunological changes in atopic dermatitis patients treated with different dosing intervals of dupilumab
14. 093 Tear fluid dupilumab levels of patients with moderate-to-severe atopic dermatitis and ocular surface disease
15. 285MO The combination of lomustine and antibody-based targeted TNF (L19TNF) as a promising treatment for recurrent glioblastoma
16. PO-1157 Comprehensive comparison of prognostic scores for patients with newly diagnosed brain metastases
17. T085 Establishment of a sustainable measurement infrastructure for standardised measurement of cardiovascular disease biomarkers within the cardiomet consortium
18. Meta-topologies define distinct anatomical classes of brain tumors linked to histology and survival
19. Anatomical phenotyping and staging of brain tumors
20. 234 Unraveling heterogeneity in pediatric atopic dermatitis: identification of serum biomarker based patient clusters.
21. 378TiP A phase I/II/IIb study to evaluate the safety and efficacy of the tumor-targeting human antibody-cytokine fusion protein L19TNF plus standard temozolomide chemoradiotherapy in patients with newly diagnosed glioblastoma
22. Stillbirth in Australia 2: Working together to reduce stillbirth in Australia: The Safer Baby Bundle initiative
23. Neurological and vascular complications of primary and secondary brain tumours: EANO-ESMO Clinical Practice Guidelines for prophylaxis, diagnosis, treatment and follow-up
24. D300 ABROCITINIB VERSUS DUPILUMAB: TIME TO IMPROVEMENT BY BODY REGION (JADE COMPARE)
25. Consistent evidenced based information for women about fetal movements is important
26. P552 RAPIDITY OF EFFICACY RESPONSE WITH ABROCITINIB VERSUS DUPILUMAB IN THE HEAD–NECK REGION (JADE COMPARE)
27. 372MO Melanoma leptomeningeal metastases: A European multicenter cohort
28. 360O Telomerase reverse transcriptase (TERT) promoter mutation and O6-methylguanine DNA methyltransferase (MGMT) promoter methylation-mediated sensitivity to temozolomide in IDH-wildtype glioblastoma: Is there a link?
29. Addressing a national crisis: the spine hospital and department's response to the COVID-19 pandemic in New York City
30. Fampridine-induced changes in walking kinetics are associated with clinical improvements in patients with multiple sclerosis
31. 407 High burden of patient-reported ocular disorders and symptoms in adults with moderate-to-severe atopic dermatitis
32. Effets à long terme du dupilumab sur les valeurs du SCORAD dans l’évaluation de la dermatite atopique modérée à sévère : résultats de l’étude de phase 3 LIBERTY AD CHRONOS
33. Efficacité et sécurité du dupilumab chez des patients adultes atteints de dermatite atopique modérée à sévère ayant des antécédents d’utilisation d’immunosuppresseur : analyse post-hoc de l’étude de phase 3 CAFÉ
34. Le dupilumab améliore les signes, les symptômes et la qualité de vie chez des patients adultes atteints de dermatite atopique non parvenus à un score IGA de 0/1
35. Toward a boot strap hypothesis of plate tectonics: Feedbacks between plates, the asthenosphere, and the wavelength of mantle convection
36. Prognostic role of the EANO ESMO classification of leptomeningeal metastases
37. Neurologic complications of cancer immunotherapies
38. 161 EUROSTAD Prospective Observational Study: Baseline Characteristics, Atopic Dermatitis Severity, and Patient-Reported Outcomes
39. 417 The effect of dupilumab on the peripheral blood T cell compartment in moderate to severe atopic dermatitis patients
40. 427 Predicting treatment response to methotrexate in atopic dermatitis patients using clinical characteristics and serum biomarkers
41. 415 Endotyping of adult and paediatric atopic dermatitis; is it one disease?
42. 418 Early identification of atopic dermatitis patients in need of systemic immunosuppressive treatment
43. 178 Effect of Dupilumab on Global Individual Signs Score Outcomes in Adults With Moderate-to-Severe Atopic Dermatitis: Combined Results From Four Phase 3 Trials
44. 621 Dupilumab in adolescents with moderate-to-severe atopic dermatitis and a history of inadequate response, or intolerance to cyclosporine: subgroup analysis from a pivotal 16-week trial
45. 714 Productivity losses in adults with atopic dermatitis (AD): A cross-sectional study from clinical practices in Europe and Canada
46. Cerebrospinal fluid cell-free tumour DNA as a liquid biopsy for primary brain tumours and central nervous system metastases
47. Intra-CSF liposomal cytarabine plus systemic therapy as initial treatment of breast cancer leptomeningeal metastasis: A randomised, open-label trial
48. PSS43 - DUPILUMAB IMPROVES ABSENTEEISM IN MODERATE-TO-SEVERE ATOPIC DERMATITIS PATIENTS COMPARED WITH PLACEBO IN PHASE 3 LIBERTY AD SOLO STUDIES
49. Tumor-treating fields: time for demystification
50. Bevacizumab may improve quality of life, but not overall survival in glioblastoma: an epidemiological study
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.